CD274 and neoplasm: Finally, atezolizumab significantly prolonged DFS in stage II–IIIA patients with PD-L1 on tumours ≥ 1% (HR: 0.66; 95% CI: 0.50–0.88; p = 0.0039) and in all patients with stage II–IIIA (HR: 0.79; 95% CI: 0.64–0.96; p = 0.020) compared to optimal supportive treatment [90].